Panobinostat (LBH589): A Potent Pan-Deacetylase Inhibitor with Promising Activity Against Hematologic and Solid Tumors
- 11 June 2009
- journal article
- review article
- Published by Taylor & Francis Ltd in Future Oncology
- Vol. 5 (5), 601-612
- https://doi.org/10.2217/fon.09.36
Abstract
The deacetylase inhibitors are a structurally diverse class of targeted antineoplastic agents that have demonstrated in vitro and in vivo preclinical activity in a wide range of malignancies. Based on this preclinical activity, several deacetylase inhibitors have undergone rapid clinical development in recent years. Among these, the deacetylase inhibitor panobinostat is one of the most widely studied, with extensive pharmacokinetic, pharmacodynamic and dose-finding data available across a wide variety of hematologic and solid tumors. Furthermore, panobinostat has demonstrated favorable clinical activity against various hematologic malignancies, most notably lymphomas and myeloid malignancies in Phase I and II studies. In this article, we discuss the preclinical data on panobinostat and emerging data from Phase I and II studies in cancer patients.This publication has 39 references indexed in Scilit:
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaClinical Cancer Research, 2008
- Role of Acetylation and Extracellular Location of Heat Shock Protein 90α in Tumor Cell InvasionCancer Research, 2008
- Clinically Relevant QTc Prolongation Is Not Associated With Current Dose Schedules of LBH589 (panobinostat)Journal of Clinical Oncology, 2008
- Chromatin Modifications and Their FunctionCell, 2007
- The Epigenomics of CancerCell, 2007
- Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic MalignanciesClinical Cancer Research, 2006
- Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Blood, 2005